Aclaris Therapeutics (ACRS) financial statements
Aclaris Therapeutics reported revenue of $8M in fiscal 2025, up 21.2% a year over 8 years.
Net income was -$65M.
Free cash flow was -$47M.
The diluted share count rose 472% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Aclaris Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $2M | $6M | $4M | $6M | $7M | $30M | $31M | $19M | $8M |
| Cost of revenue | — | $1M | $4M | $4M | $5M | $5M | $4M | $3M | $3M | $2M |
| Gross profit | — | $476,000 | $3M | $172,000 | $1M | $2M | $26M | $28M | $16M | $6M |
| Research and development | $33M | $36M | $61M | $64M | $29M | $44M | $78M | $98M | $34M | $53M |
| Selling, general and admin | $15M | $19M | $26M | $28M | $21M | $24M | $25M | $32M | $22M | $22M |
| Operating income | -$49M | -$54M | -$85M | -$111M | -$51M | -$90M | -$90M | -$97M | -$142M | -$76M |
| Pre-tax income | -$48M | -$70M | -$82M | -$114M | -$51M | -$91M | -$87M | -$89M | -$132M | -$65M |
| Income tax | — | -$2M | — | — | -$182,000 | — | — | -$367,000 | — | — |
| Net income | -$48M | -$69M | -$133M | -$161M | -$51M | -$91M | -$87M | -$88M | -$132M | -$65M |
| EPS (diluted) | -$2.25 | -$2.44 | -$4.03 | -$3.90 | -$1.20 | -$1.60 | -$1.33 | -$1.27 | -$1.71 | -$0.53 |
| Diluted shares | 21M | 28M | 33M | 41M | 43M | 57M | 65M | 70M | 77M | 123M |
| Gross margin | — | 28.3% | 52.7% | 4.1% | 20.8% | 30.3% | 86.5% | 89.0% | 85.1% | 73.3% |
| Operating margin | — | -3230.0% | -1378.3% | -2627.3% | -785.4% | -1327.1% | -302.0% | -311.6% | -758.2% | -975.9% |
| Net margin | — | -4071.5% | -2158.0% | -3817.2% | -787.0% | -1344.0% | -292.1% | -283.1% | -705.5% | -829.6% |
Balance sheet
Fiscal years, from Aclaris Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $174M | $209M | $168M | $75M | $54M | $226M | $230M | $182M | $204M | $151M |
| Receivables | — | $481,000 | $563,000 | $704,000 | $772,000 | $623,000 | $484,000 | $298,000 | $318,000 | — |
| Inventory | — | — | $791,000 | $0 | — | — | — | — | — | — |
| Total current assets | $139M | $200M | $179M | $84M | $57M | $205M | $232M | $129M | $126M | $96M |
| Property, plant and equipment | $481,000 | $2M | $2M | $2M | $2M | $1M | $1M | $2M | $1M | $761,000 |
| Goodwill | — | $19M | $19M | — | — | — | — | — | — | — |
| Total assets | $176M | $244M | $276M | $98M | $71M | $251M | $255M | $197M | $220M | $160M |
| Total current liabilities | $6M | $13M | $27M | $22M | $15M | $23M | $22M | $31M | $32M | $29M |
| Total liabilities | $7M | $18M | $60M | $28M | $33M | $54M | $57M | $40M | $65M | $57M |
| Shareholders' equity | $169M | $225M | $215M | $70M | $38M | $197M | $198M | $157M | $156M | $103M |
| Net debt | -$30M | -$20M | -$57M | -$34M | -$22M | -$27M | -$45M | -$40M | -$25M | -$20M |
Cash flow
Fiscal years, from Aclaris Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$35M | -$55M | -$101M | -$96M | -$39M | -$52M | -$68M | -$78M | -$20M | -$47M |
| Capital spending | $232,000 | $1M | $1M | $2M | $453,000 | $308,000 | $605,000 | $1M | $121,000 | $111,000 |
| Free cash flow | -$35M | -$56M | -$102M | -$98M | -$39M | -$52M | -$68M | -$80M | -$20M | -$47M |
| Stock-based compensation | $6M | $14M | $20M | $16M | $11M | $14M | $15M | $21M | $11M | $12M |
| Net borrowing | — | — | $30M | — | $11M | — | — | — | — | — |
| Free cash flow margin | — | -3321.3% | -1661.0% | -2319.8% | -603.0% | -775.7% | -229.1% | -254.8% | -107.9% | -603.4% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ACRS.
Open ACRS in InvestinglyQuestions
What was Aclaris Therapeutics's revenue in 2025?
$8M in fiscal 2025, from its 10-K filing.
How much free cash flow does Aclaris Therapeutics generate?
-$47M in fiscal 2025 (operating cash flow minus capital spending).
From Aclaris Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.